Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $7.4B. The Maz Rating grades it against the other companies in its sector.
Amneal Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $21.12, Amneal Pharmaceuticals, Inc. trades at 48.7x trailing earnings, 2.3x sales and 13.2x book value, with an EV/EBITDA of 15.7. Over the last twelve months it generated about $3.2B of revenue and $151M of net income. It runs a gross margin of 40.2%, an operating margin of 15.6% and a net margin of 4.6%. It shows return on equity of 131.7%, return on invested capital of 10.8% and a free cash flow yield of 0.6%. On the balance sheet: a debt-to-equity ratio of 6.18 and a current ratio of 1.87. Over the past 52 weeks the share price ranged from $11.39 to $22.07, with a beta of 1.21.
Amneal Pharmaceuticals, Inc. does not currently pay a dividend.
18 Wall Street analyst ratings cover the stock: 12 Buy and 6 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.